Clinical application experience of asfotase alfa for a young patient with childhood hypophosphatasia
Osteoporosis and Bone Diseases · 2019
DOI: 10.14341/osteo10136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Osteoporosis and Bone Diseases, 2019. Verfasst von Nataliya Y. Kalinchenko und 5 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Hypophosphatasia (HPP) is a rare hereditary metabolic disease characterized by defective bone and dental mineralization, systemic complications that lead to disability of patients. HPP is classified into six forms according to the age of onset and severity of its clinical picture. The disease is caused by a reduced activity of the tissue nonspecific alkaline phosphatase (TNSALP) and elevated concentrations of pyrophosphates. Asfotase alfa is the only pathogenetic enzyme replacement therapy with recombinant human bone-targeted TNSALP approved for treatment of patients with perinatal, infantile and juvenile‐onset HPP. This treatment is associated with improved skeletal mineralization, respiratory function and overall survival in infants and young children with life-threatening hypophosphatasia. The world experience in application of recombinant alkaline phosphatase in adults is very limited. We present a clinical case that describes the first Russian experience in the use of asfotase alfa in an 18-year-old patient with late diagnosis of childhood-onset HPP.
Zitieren
APA
Kalinchenko, N. Y., Golounina, O. O., Grebennikova, T. A., Melnichenko, G. A., Tiulpakov, A. N., & Belaya, Z. E. (2019). Clinical application experience of asfotase alfa for a young patient with childhood hypophosphatasia. Osteoporosis and Bone Diseases. https://doi.org/10.14341/osteo10136
Vancouver
Kalinchenko NY, Golounina OO, Grebennikova TA, Melnichenko GA, Tiulpakov AN, Belaya ZE. Clinical application experience of asfotase alfa for a young patient with childhood hypophosphatasia. Osteoporosis and Bone Diseases. 2019. doi:10.14341/osteo10136
BibTeX
@article{Kalinchenko2019,
author = {Kalinchenko, Nataliya Y. and Golounina, Olga O. and Grebennikova, Tatiana A. and Melnichenko, Galina A. and Tiulpakov, Anatoly N. and Belaya, Zhanna E.},
title = {Clinical application experience of asfotase alfa for a young patient with childhood hypophosphatasia},
journal = {Osteoporosis and Bone Diseases},
year = {2019},
doi = {10.14341/osteo10136}
}
EUVIMED